merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>by offering a safer, FDA-approved alternative</answer>
<question_number>2</question_number>
<answer>by providing a direct, lower-cost option for patients</answer>
<question_number>3</question_number>
<answer>lack of oversight and safety risks</answer>
<question_number>4</question_number>
<answer>to undercut compounding pharmacies and regain customers</answer>
<question_number>5</question_number>
<answer>it would eliminate the legal basis for mass compounding</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>increased demand for non-covered weight-loss medications</answer>
<question_number>8</question_number>
<answer>by positioning its vials as a safer option</answer>
<question_number>9</question_number>
<answer>the FDA's shortage list</answer>
<question_number>10</question_number>
<answer>lower pricing to signal a challenge to compounding pharmacies</answer>